Study Group* Dysmetabolic iron overload syndrome (DIOS) is a common cause of hyperferritinemia, accounting for a mild increase of iron stores in insulin-resistant subjects. Iron removal could improve insulin sensitivity. We performed a prospective, randomized, controlled trial (NCT01015525) in nondiabetic DIOS patients with hepatic iron >50 lmol/g at magnetic resonance imaging to compare the metabolic and hepatic outcomes of 1-year maintenance of serum ferritin levels <50 lg/L by bloodletting associated with lifestyle and diet advice (LFDA) to those of LFDA only. Patients were randomly assigned (1:1) with stratification by center (n 5 8) and hyperglycemia (>5.6 mmol/L). Sample size was calculated to provide 90% power and a difference in fasting glycemia of 0.25 mmol/L. Analysis was done in an intention-to-treat population. In 2010-2014, 146 patients were randomly assigned to receive venesections with LFDA and 128 to LFDA only. At the end of the study, comparison of iron-depleted patients and controls showed ferritin levels 71 6 48 lg/L after removal of 4.9 6 1.6 L of blood versus 733 6 277 lg/L (P < 0.0001), glycemia 5.44 6 0.7 versus 5.49 6 0.7 mmol/L (P 5 0.57), body weight 10.5 6 4.3% versus -0.6 6 3.3% (P 5 0.03), homeostasis model of assessment of insulin resistance 3.39 versus 2.40 (P 5 0.002), alanine aminotransaminase 33 6 22 versus 37 6 21 IU/L (P 5 0.10), aspartate aminotransaminase 27 6 13 versus 27 6 10 IU/L (P 5 0.81), gamma-glutamyl transferase 54 6 138 versus 49 6 35 IU/L (P 5 0.72), Fatty Liver Index 58.9 6 24.6 versus 61.2 6 22.9 (P 5 0.37), and Fibrosis-4 score 1.5 6 0.6 versus 1.30 6 0.6 (P 5 0.51). Fatigue occurred in 25.3% of venesected patients versus 2.3% of controls (P < 0.0001). In the subgroup of patients who lost weight, glycemia, homeostasis model of assessment of insulin resistance, serum ferritin, lipid profile, and liver function tests improved irrespective of bloodletting. Conclusion: In DIOS patients, iron depletion by bloodletting does not improve metabolic and hepatic features, is associated with weight gain, and is not as well tolerated as expected; sustained modification of diet and lifestyle habits remains the first therapeutic intervention in DIOS. (HEPATOLOGY 2017;65:465-474).
I
nsulin resistance-associated hepatic iron overload, also termed dysmetabolic iron overload syndrome (DIOS), was first described in the late 1990s. (1, 2) It corresponds with a mild increase of both liver and body iron stores (3) associated with various components of the metabolic syndrome in the absence of any identifiable cause of iron excess. It accounts for most cases of hyperferritinemia referred to outpatient clinics and is much more frequent than genetic hemochromatosis. (4) The liver may be either normal or steatotic with
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nonalcoholic fatty liver disease (NAFLD). (5) DIOS shares the same cause as NAFLD, i.e., insulin resistance; and about 10% of DIOS patients have type 2 diabetes. (6) The role of iron excess in the development or the worsening of insulin resistance and, then, in the occurrence of diabetes and of NAFLD remains debated. Epidemiological studies have shown that elevated serum ferritin values were associated with a higher risk of developing type 2 diabetes (7) and correlated with serum insulin and serum glucose levels, (8) the best biological predictive factor of incident diabetes. (9, 10) In early and small studies, achievement of low body iron stores by bloodletting (11) (12) (13) or low-iron diet (14) was associated with decreased insulin resistance. This was not confirmed by a recent Australian study from Adams et al., (15) who failed to find any improvement in both insulin resistance and steatosis in phlebotomized NAFLD patients. However, as stressed by Ryan et al., (16) only a few patients had increased hepatic iron in this study.
The aim of the present study was to assess, in a large population of DIOS patients with well-defined hepatic iron excess, whether iron depletion by sustained phlebotomy may improve insulin resistance and liver tests.
Patients and Methods

STUDY DESIGN AND PATIENTS
The SAIGNEES study was a multicenter, openlabeled, randomized, controlled phase 3 trial of 1-year maintenance of serum ferritin levels <50 lg/L by bloodletting associated with lifestyle and diet advice (LFDA) versus LFDA only in nondiabetic DIOS patients. Adult subjects with DIOS were recruited from January 2010 to May 2014 in eight French hospitals (Angers, Clermont-Ferrand, La Roche Sur Yon, Limoges, Nantes, Orleans, Rennes, and Saint-Malo). DIOS was diagnosed as follows: (1) liver iron concentration, measured by magnetic resonance imaging, (17) >50 lmol/g dry weight; (2) presence of one of the following metabolic features at least: body mass index (BMI) >25 kg/m 2 , waist size >80 cm in females and >93 cm in males, blood pressure 130/85 mm Hg or antihypertensive drug therapy, fasting blood glucose >5.6 mmol/L but <7 mmol/L, serum triglyceride levels >1.7 mmol/L, serum high-density lipoprotein (HDL) cholesterol levels <1.29 mmol/L for females and <1.03 mmol/L for males or cholesterol-lowering therapy; and (3) absence of the following conditions: diabetes mellitus, alcohol consumption >20 g/day in females and >30 g/day in males, homozygosity for the C282Y mutation of the HFE gene, aceruloplasminemia, hematological disorder, acute or chronic inflammatory disease, viral hepatitis, and autoimmune or cholestatic liver disease. The study (clinicaltrials.gov NCT01045525) was approved by the review board of the ethics committee of Rennes. All patients provided written informed consent.
RANDOMIZATION AND MASKING
Subjects were prospectively randomized in a 1:1 fashion to iron depletion by phlebotomy with lifestyle advice versus lifestyle advice only. Randomization was performed using computer software. Stratification was made according to baseline values of fasting serum glucose (<5.6 mmol/L or not). The study was openlabeled.
PROCEDURES Iron Depletion by Bloodletting
Subjects randomized to iron depletion underwent two phases of treatment. The initial phase consisted of bimonthly phlebotomies (ranging 350-450 mL according to body weight and sex) with the objective to achieve serum ferritin levels <50 lg/L with hemoglobin levels >11 g/dL. Then, the maintenance phase consisted of bimonthly 350-450 mL phlebotomy on the basis of serum ferritin measurement every 2 months in order to maintain serum ferritin <50 lg/L and hemoglobin >11 g/dL.
Lifestyle Advice
All subjects received written dietary recommendations promoting a healthy and varied diet, in the form of two books edited by the French National Program of Nutrition and Health (http://www.inpes.sante.fr), and were advised to engage in physical activity for at least 30 minutes/day. They were left free to consult a dietician.
Clinical Assessment
It was performed at baseline and 12 months after randomization and included medical history; medications; questionnaires about alcohol consumption, eating habits, and physical activity; BMI; waist circumference; and systolic and diastolic blood pressure. Waist circumference was measured according to the recommendations of the Third National Health and Nutrition Examination Study (http://www.cdc. gov). Blood pressure was measured on a subject lying down, at rest for at least 5 minutes. Three successive measurements spaced at 2 minutes were performed using automatic test equipment. The value used was the average of the last two measures.
Biochemical Assessment
A fasting venipuncture and a 75 g oral glucose tolerance test (OGTT) were performed at baseline and at 12 months. Biochemical testing included blood cell count, aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), gamma-glutamyl transferase (GGT), HDL and low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, insulin, hemoglobin A1c, iron parameters (iron, transferrin, ferritin, and transferrin saturation), C-reactive protein, and adiponectin. The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated as (insulin T0 3 glucose T0)/22.5, modified Matsuda index as 1,000= ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ½ðglucose T0 3 insulin T0Þ 3 ðglucose T30 3 insulin T30Þ p , and insulinogenic index as the ratio of the increment of the insulin concentration over the first 30 minutes of the OGTT to the increment in blood glucose over the same period (insulin T0-T30/glucose T0-T30). Hepatic fibrosis was assessed using the Fibrosis-4 score (18) and steatosis using the Fatty Liver Index. (19) 
OUTCOMES
The primary outcome was the mean value of fasting blood glucose 1 year after randomization.
Secondary outcomes were (1) variations of metabolic features from baseline to end of treatment; (2) insulin resistance measured by HOMA-IR, modified Matsuda index, and insulinogenic index based upon a 75 g OGTT with measurement of glycemia and insulinemia at baseline and 30 and 120 minutes after glucose ingestion, 1 year after randomization; (3) serum adiponectin levels 1 year after randomization; (4) serum Creactive protein levels 1 year after randomization; (5) liver function tests; and (6) Fatty Liver Index and Fibrosis-4 scores.
STATISTICAL ANALYSIS
An a priori power calculation indicated that a sample size of 270 subjects would provide 90% power to determine a difference in fasting blood glucose of 0.25 mmol/L, assuming a standard deviation of 0.61 mmol/ L, a two-sided P value of 0.05, and a dropout rate of 10%. Finally, the standard deviation of fasting glycemia was 0.71 at the end of the study; a posteriori power calculation indicated 80% power, with a two-sided P value of 0.05 to determine a difference in fasting glycemia of 0.25 mmol/L.
The statistical analysis, prospectively defined, was done by intention to treat (i.e., in all analyses, patients were grouped according to their original randomized treatment) with SAS statistical software (version 9.4; SAS Institute, Cary, NC). Continuous variables were expressed by mean and standard deviation, and categorical variables were expressed by the number of patients and percentages. Baseline characteristics were compared between groups using Student t test for continuous variables and chi-squared test or Fisher's exact test for categorical variables. Student t tests were also performed between groups on the variation of continuous variables (between baseline and the end of study).
The primary and secondary outcomes were evaluated first with Student t test and chi-squared test, followed by analyses of variance with adjustment on the variation of weight. Regarding the insulin-related parameters, analyses of variance with adjustment on the variation of weight and insulin at baseline were used. The same analysis was performed in subgroups of patients who lost weight. All statistical tests had a significance level of 0.05.
Results
PATIENT GROUPS AND CHARACTERISTICS AT BASELINE
Between January 8, 2010, and May 30, 2014, 274 patients were randomly assigned to receive venesections with LFDA (iron depletion group) and 128 to LFDA only (control group). Seven patients withdrew prior to the end of the study, 1 in the iron depletion group because he went abroad and 6 in the control arm (1 suddenly died and 5 withdrew by personal decision). Finally, 267 patients were analyzed, 145 in the iron depletion arm and 122 in the control arm ( Fig. 1) . Baseline characteristics are summarized in Table 1 . All patients were Caucasian, and most were middle-aged males. Mean BMI was 28.5 6 3.6 kg/m 2 . Obesity was present in 31.1% of patients, increased waist circumference in 88%, hypertension in 54%, elevated serum triglycerides in 55.1%, and hypercholesterolemia in 42.3%. Mean glycemia was 5.61 6 0.61 mmol/L. Hyperglycemia (fasting blood glucose >5.6 mmol/L) was observed in 36.9% of patients. Metabolic syndrome, defined according to the International Diabetes Federation, was present in 59.5%. Mean alcohol consumption was 90 6 80 g/week. Increase in serum ALT levels was present in 29.3% of patients, but ALT levels were greater than 2 times the upper limit of normal in 7% only. According to Fibrosis-4 score, 3 patients had bridging hepatic fibrosis or cirrhosis. According to the Fatty Liver Index, steatosis was present in 59.1% of patients, uncertain in 29.3%, and absent in 11.6%. Liver biopsy was performed in 7 patients who all presented with steatosis. 
IRON REMOVAL
During the initial phase of treatment, a mean of 12 6 4 bimonthly phlebotomies was performed in the iron depletion group. This corresponded to a mean of 4.9 6 1.6 L of blood removed, i.e., 2.45 6 0.8 g of iron. At the end of the initial phase, the mean value of serum ferritin levels was 62 6 37 lg/L. The threshold of 50 lg/L was achieved in 72 (50%) patients, while serum ferritin levels were comprised between 50 and 100 lg/L in 55 (38%) and greater than 100 lg/L in 17 (12%) patients. During the maintenance phase, 91 (62%) of the iron-depleted patients had a mean of 2 6 1 phlebotomies. At the end of the study, the threshold of 50 lg/L was achieved in 51 (35%) patients, while serum ferritin levels were between 50 and 100 lg/L in 73 (50%) and >100 lg/L in 21 (15%) patients. The main causes of nonachievement of the goal of serum ferritin <50 lg/L at the end of treatment were adverse events (43%) and poor adherence to phlebotomies (67%). There was no serious adverse event related to treatment. Dizziness, hypotension, and vagal malaise related to iron-depletion therapy were reported in 3, 2, and 5 patients, respectively. Anemia, defined as hemoglobin level <12 g/dL in females and <13 g/dL in males, was observed in 6 patients. Fatigue was reported in 37 patients (25.3%) of the iron-depleted group versus 3 patients (2.3%) in the control group (P < 0.0001).
LIFESTYLE AND DIET
The percentage of patients who consulted a dietician was identical (12%) in the two arms. Physical activity scores during sport and leisure did not significantly change during the study in the two groups. Variation in alcohol consumption was not different in the two groups, with a mean of 210 g/week. Mean variation of BMI was 10.13 6 1.22 kg/m 2 in the iron depletion group versus 20.17 6 0.94 kg/m 2 in the control group (P 5 0.03). Mean percentage of variation in body weight was 10.5 6 4.3% in the iron depletion group versus 20.6 6 3.3% in the control group (P 5 0.03). Percentages of patients whose weight decreased, remained stable (61 kg), or increased were 21%, 41%, and 38%, respectively, in the iron depletion group versus 26%, 53%, and 21%, respectively, in the control group (P 5 0.009).
FASTING BLOOD GLUCOSE
There was no difference in end-of-treatment fasting blood glucose between the iron depletion and control groups (5.44 6 0.71 versus 5.49 6 0.70, respectively; P 5 0.57), even after adjustment for variation of weight (P 5 0.44). A stepwise multivariate analysis of the variation of glycemia was performed. The following variables were included in the analysis: treatment group, presence of HTA, variations between baseline and end-of-study of weight, waist circumference, hemoglobin, baseline cholesterol, serum ferritin, and liver enzyme values. Weight variations and GGT values were the only two variables independently and positively associated (P 5 0.01 and P 5 0.03, respectively) with the variation of glycemia. As scheduled, analysis was performed in subgroups of patients according to baseline values of fasting glycemia. One hundred and thirty-seven (51%) patients had glycemia 5.6 mmol/ L at inclusion, of whom 74 were randomized in the iron depletion group and 63 in the control group. There was no difference in end-of-treatment fasting blood glucose between the two groups (5.81 6 0.74 versus 5.83 6 0.77, respectively; P 5 0.91), even after adjustment for variation of weight (P 5 0.71). One hundred and thirty (49%) patients had glycemia <5.6 mmol/L at inclusion, of whom 71 were randomized in the iron depletion group and 59 in the control group. There was no difference in end-of-treatment fasting blood glucose between the iron depletion and control groups (5.06 6 0.4 versus 5.13 6 0.4, respectively; P 5 0.27), even after adjustment for variation of weight (P 5 0.24). Per protocol analysis comparing the 51 patients with serum ferritin levels <50 lg/L 1 year after randomization with controls was performed. There was no difference in end-of-treatment fasting blood glucose between the iron depletion and control groups (5.45 6 0.58 versus 5.49 6 0.7; P 5 0.72) even after adjustment on weight variation (P 5 0.65).
MARKERS OF INSULIN RESISTANCE
There was no significant effect of iron depletion on mean serum values of triglycerides, HDL and LDL cholesterol, mean values of systolic and diastolic blood pressure, and percentage of hypertensive patients ( (Table 3) . A stepwise multivariate analysis of the variation of HOMA-IR was performed. The following variables were included in the analysis: treatment group, presence or absence of HTA, variations between baseline and end-of-study weight, waist circumference, hemoglobin, baseline cholesterol, serum ferritin, and liver enzymes values. Weight variations (P < 0.001), GGT values (P < 0.01), treatment group (P < 0.01), and arterial hypertension (P 5 0.02) were significantly and positively associated with variation of HOMA-IR. There was no difference in end-of-treatment adiponectin serum levels between the iron depletion and control groups (6.2 6 4.3 versus 6.5 6 3.9, respectively; P 5 0.53) and in end-of-treatment C-reactive protein serum levels between the two groups (2.1 6 1.8 versus 2.4 6 3.1, respectively; P 5 0.24) even after adjustment for variation of weight (P 5 0.70 and P 5 0.20, respectively).
LIVER TESTS AND SCORES
End-of-study AST, ALT, and GGT did not differ between the iron-depleted and control groups ( Table  2 ). After adjustment for weight variation, serum ALT levels were significantly lower (P 5 0.03) in the irondepleted group. Fibrosis-4 and Fatty Liver Index scores were not different according to groups.
SUBGROUP ANALYSIS ACCORDING TO WEIGHT LOSS
Sixty-three patients lost >1 kg of body weight: 31 (21%) in the iron depletion group and 32 (26%) in the control group. Glycemia, insulinemia, HOMA-IR, HDL and LDL cholesterol, triglycerides, and liver enzymes were or tended to be improved in these patients regardless of the treatment group (Table 4) .
Discussion
The present study demonstrates that, in patients with DIOS, removal of iron excess by phlebotomies has no significant metabolic and hepatic effects. Even more, *Insulinogenic index was calculated as as the ratio of the increment of the insulin concentration over the first 30 minutes of the OGTT to the increment in blood glucose over the same period (insulin T0-T30/glucose T0-T30). † Modified Matsuda index was calculated as 1; 000= ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi ½ðglucose T0 3 insulin T0Þ 3 ðglucose T30 3 insulin T30Þ p bloodletting may contribute to weight gain and to the worsening of some insulin resistance-related features. Blood glucose was chosen as the primary endpoint for the following reasons.
First, insulin resistance is the main determinant of both DIOS (1) and NAFLD. (20) Blood glucose is one of the best surrogate markers reflecting the degree of insulin resistance and the risk of forthcoming type 2 diabetes. (9) The epidemiological demonstration of an association between blood glucose and body iron store concentrations was made by Finnish authors. (8) Since then, a few clinical trials (11) (12) (13) 15, (21) (22) (23) have reported conflicting results about the effects of phlebotomy therapy on blood glucose and markers of insulin resistance in patients with various metabolic abnormalities. In all but the study conducted by Piperno et al. (22) DIOS patients were mixed with NAFLD patients with no iron excess. In addition, most studies were not randomized, (11, 13, 22) included a limited number of patients, (11, 15, (21) (22) (23) (24) and mixed those with and those without diabetes. (11, 15, 21, 22, 24) Second, Fernandez-Real et al. reported a positive relationship between serum ferritin levels and insulin resistance and proposed serum ferritin as a component of the insulin resistance syndrome. (25) In a controlled randomized trial conducted in 28 patients with type 2 diabetes and elevated serum ferritin, they found that iron removal improved both insulin sensitivity and beta cell function but had no significant effect on blood glucose. (12) Facchini et al., in a randomized study of 42 patients, mainly with diabetes, showed that iron depletion was associated with a decrease of both fasting and glucose-stimulated plasma insulin concentrations in a subgroup of 17 hyperferritinemic subjects with nonbiopsy-proven NAFLD. (11) Piperno et al. compared the respective effects of venesection therapy and diet restriction in 44 subjects with DIOS. (22) They found that diet restriction only resulted in a significant decrease in blood glucose. Valenti et al., in a casecontrol study of 128 patients without diabetes but with NAFLD and either elevated serum ALT levels or increased serum ferritin levels or both, showed that serum insulin, serum glucose, and HOMA-IR improved in iron-depleted patients. (13) Finally, Adams et al., in a randomized controlled study, showed that iron depletion failed to improve blood glucose, HOMA-IR, and Insulin Sensitivity Index in 61 patients with NAFLD and in a limited subgroup of 36 patients with hyperferritinemia. (15) Compared to these previous studies, we included a much larger sample of patients, which allowed for a satisfactory statistical power. Moreover, all of our subjects had hepatic iron excess demonstrated using a well-validated method. (17) Finally, our study was controlled and randomized with stratification on baseline serum glucose. As blood glucose value is associated in a continuous manner with the risk of diabetes, (9) the present data support the conclusion that, in DIOS patients without diabetes, iron depletion has no effect on the risk of developing diabetes, irrespective of the initial level of that risk.
Third, it would have not been realistic to propose liver biopsy as the primary endpoint in our study because, in daily practice, it is rarely performed in DIOS patients. Indeed, most of them have no increased serum transaminase levels-as illustrated by the present data-and the risk of severe fibrosis, which is very low in the absence of cofactors of liver disease, can be ruled out by noninvasive tests. Requiring histological endpoints would have resulted in a selection bias and then in hardly conclusive results.
Our results raised concerns about putative deleterious effects of phlebotomy therapy in DIOS patients. Indeed, despite both groups having comparable baseline BMI and receiving similar lifestyle advice, BMI decreased by 0.5% in controls but increased by 0.4% in venesected patients (P 5 0.03). This is in line with the observation of a trend to weight gain in venesected patients in the studies from Valenti et al. (13) and from Adams et al. (15) that did not reach statistical significance, likely due to insufficient sample size. Weight gain could be partly related to looser motivation of venesected patients for lifestyle recommendations because of the falsely reassuring feeling of being already treated.
Conflicting results about the effects of venesection therapy on HOMA-IR index, a surrogate marker of insulin resistance, have been reported. Some authors found that HOMA-IR index decreased in venesected patients, (11) (12) (13) while others did not find any effect of iron removal. (15, 21, 24) In the present study, we showed that HOMA-IR index increased in venesected patients, mainly due to an increase in serum insulin. This was significant at univariate analysis and confirmed at multivariate analysis, which showed that increase in HOMA-IR index was independently explained by both bloodletting and weight gain. Basal hypersecretion of insulin is viewed as an independent abnormality in the pathogenesis of type 2 diabetes and has been shown to predict diabetes development, independently of insulin resistance. (26) This increase in fasting insulin levels, besides the improvement of hyperferritinemia, suggests the absence of benefit of iron depletion on the risk of type 2 diabetes. Nevertheless, the deleterious effect of venesection therapy per se is likely to remain weak compared to that induced by weight variation. Our study demonstrates that weight variation is, in fact, the primary determinant of the evolution of not only HOMA-IR index but also metabolic features and liver tests in DIOS patients without diabetes. This was well illustrated by the improvement of blood glucose, LDL and HDL cholesterol, triglycerides, ALT, and GGT in patients who had lost weight and by the absence of a clinically significant effect of iron removal on these parameters in these patients (Table 4) .
It could be discussed that iron depletion was insufficient to reach significant effects in the present study. However, previous studies had conflicting results independently of bloodletting scheme and endpoints of serum ferritin and serum hemoglobin. Moreover, analysis of the subgroup of our patients having achieved serum ferritin levels <50 lg/L at 1 year failed to show any significant effect of venesection therapy on primary and secondary outcomes.
In addition, venesection therapy was not as well tolerated as expected. (27) Indeed, a significant proportion of venesected patients experienced fatigue and mild malaise, as reported by Piperno et al. (22) This and the poor adherence to phlebotomy we observed render it difficult to propose a more intensive scheme of bloodletting in routine practice.
In conclusion, in DIOS patients, iron depletion by phlebotomy has no significant effect on serum glucose level or on liver biochemical tests and scores, may aggravate insulin resistance, is associated with weight gain, and is poorly tolerated. Weight loss alone is associated with improvement in most metabolic features including glycemia and insulin resistance as well as in serum ferritin and liver tests. Sustained modification of diet and lifestyle habits remains the first therapeutic intervention in these patients.
